FDA approves Tosymra (Shumaqutan nasal spray, 10mg) for continued treatment of migraines in adults
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, DrReddy,of the
http:// pharmaceuticalin India, said: "It's not a good timeReddy's Laboratories Ltd and sub-
company(http://Promius Pharma announced that the U.SFood andDrug(http://Administration (
FDA(http://) has approved Tosymra (Shumaqutam nasal spray, 10 mg) for continued treatment for adult migraines with or without warningTosymra is the latest product (http:// to join Promius Pharmaceuticals' acute migraine treatment portfolio Tosymra nasal spray uses a proprietary new excipient, Intravail, to achieve a shumaqutam blood level similar to a 4mg shumaqutam subcutaneous injection and to achieve rapid results independent studies have shown that 26-40% of migraine sufferers who receive their current medication do not have a good control of the condition Reliable and effective treatment options are still needed for patients who experience the effects of migraine decay and destructiveeffect Tosymra is a foggy nasal spray that works quickly and is well tolerated, and the drug is available in the U.S to offer a new treatment option for migraine sufferers in the region
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
